ATE198830T1 - Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems - Google Patents

Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems

Info

Publication number
ATE198830T1
ATE198830T1 AT92907711T AT92907711T ATE198830T1 AT E198830 T1 ATE198830 T1 AT E198830T1 AT 92907711 T AT92907711 T AT 92907711T AT 92907711 T AT92907711 T AT 92907711T AT E198830 T1 ATE198830 T1 AT E198830T1
Authority
AT
Austria
Prior art keywords
nervous system
degenerative diseases
pct
treat degenerative
anabaseine
Prior art date
Application number
AT92907711T
Other languages
English (en)
Inventor
John A Zoltewicz
William R Kem
Edwin M Meyer
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Application granted granted Critical
Publication of ATE198830T1 publication Critical patent/ATE198830T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92907711T 1991-03-01 1992-02-27 Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems ATE198830T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66286791A 1991-03-01 1991-03-01
PCT/US1992/001451 WO1992015306A1 (en) 1991-03-01 1992-02-27 Use of nicotinic analogs for treatment of degenerative diseases of the nervous system

Publications (1)

Publication Number Publication Date
ATE198830T1 true ATE198830T1 (de) 2001-02-15

Family

ID=24659568

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92907711T ATE198830T1 (de) 1991-03-01 1992-02-27 Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems

Country Status (12)

Country Link
US (4) US5516785A (de)
EP (1) EP0573568B1 (de)
JP (1) JP2657583B2 (de)
KR (2) KR0175638B1 (de)
AT (1) ATE198830T1 (de)
AU (1) AU652434B2 (de)
CA (2) CA2105071C (de)
DE (1) DE69231658T2 (de)
DK (1) DK0573568T3 (de)
ES (1) ES2153357T3 (de)
GR (1) GR3035542T3 (de)
WO (1) WO1992015306A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0573568B1 (de) * 1991-03-01 2001-01-24 University Of Florida Research Foundation, Inc. Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems
US5276043A (en) * 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
KR100272614B1 (ko) * 1992-08-31 2000-11-15 엠. 잭 오해니언 신경계의 퇴행성 질환의 치료에 유용한 아나바세인 유도체
US5510355A (en) * 1994-09-06 1996-04-23 Bencherif; Merouane Depolarizing skeletal muscle relaxants
JP3219946B2 (ja) * 1994-09-22 2001-10-15 大鵬薬品工業株式会社 新規製造中間体及びピリジン誘導体の製造方法
US5723477A (en) * 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5703100A (en) * 1994-11-10 1997-12-30 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5677459A (en) * 1994-11-10 1997-10-14 Sibia Neurosciences, Inc. Methods for the preparation of modulators of acetylcholine receptors
US5705512A (en) * 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5594011A (en) * 1994-11-10 1997-01-14 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
JP2002511068A (ja) 1997-05-30 2002-04-09 ニューロサーアチ・アクティーゼルスカブ アザシクロオクタン及びヘプタン誘導体、その製造方法及びこれを用いて治療する方法
JP2002516869A (ja) * 1998-06-05 2002-06-11 レジェンド コート テクノロジーズ モノアミンオキシダーゼ（ｍａｏ）阻害剤とその使用
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6750234B2 (en) * 2001-03-08 2004-06-15 University Of Kentucky Research Foundation Methods for increasing leptin levels using nicotinic acid compounds
US7091357B2 (en) 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US7160551B2 (en) * 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
US7244745B2 (en) 2002-08-30 2007-07-17 Memory Pharmaceuticals Corp. Heterocyclic compounds, methods for the preparation thereof, and uses thereof
MXPA05003317A (es) 2002-09-25 2005-07-05 Memory Pharm Corp Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
US7736636B2 (en) * 2003-02-12 2010-06-15 Shaker Mousa Method for treating occlusive vascular diseases & wound healing
CA2463719A1 (en) * 2003-04-05 2004-10-05 F. Hoffmann-La Roche Ag Nucleotide analogs with six membered rings
RU2259364C1 (ru) * 2004-04-01 2005-08-27 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, включающие фрагмент пиперидин-2-ила-, фокусированные библиотеки и фармацевтические композиции
US7816356B2 (en) 2003-11-14 2010-10-19 Daniel Yohannes Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands
EP1735306A2 (de) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazole, benzothiazole, benzoisothiazole, benzisoxazole und deren herstellung und verwendungen
US20050288333A1 (en) * 2004-06-08 2005-12-29 Kem William R Controlling angiogenesis with anabaseine analogs
KR20060038010A (ko) * 2004-10-29 2006-05-03 재단법인서울대학교산학협력재단 니코틴산을 포함하는, 갭 결합을 통한 세포간 정보전달의억제 및 항상성의 불균형과 관련된 질환의 예방 또는치료용 조성물
US7930222B2 (en) * 2006-06-27 2011-04-19 Quiq, Inc. Method and system for preparing a set of paired identification labels
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009146031A1 (en) * 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
KR20120054639A (ko) * 2009-08-21 2012-05-30 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 아나바세인 화합물의 제어-방출성 제형 및 그의 용도
WO2012007365A1 (en) * 2010-07-12 2012-01-19 F. Hoffmann-La Roche Ag 1-hydroxyimino-3-phenyl-propanes
WO2012031220A2 (en) 2010-09-03 2012-03-08 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
AU2012249487A1 (en) * 2011-04-28 2013-11-07 Rcp Development, Inc. Methods of administering anatabine to treat Autism Spectrum Disorders and seizure disorders
WO2013032558A2 (en) 2011-08-29 2013-03-07 Rock Creek Pharmaceuticals, Inc. Products for anti-inflammation support
US10340082B2 (en) 2015-05-12 2019-07-02 Capacitor Sciences Incorporated Capacitor and method of production thereof
US10347423B2 (en) 2014-05-12 2019-07-09 Capacitor Sciences Incorporated Solid multilayer structure as semiproduct for meta-capacitor
AU2015259291A1 (en) 2014-05-12 2016-11-24 Capacitor Sciences Incorporated Energy storage device and method of production thereof
CN107592939B (zh) 2014-11-04 2020-05-05 电容器科学股份公司 储能器件及其生产方法
RU2017128756A (ru) 2015-02-26 2019-03-27 Кэпэситор Сайенсиз Инкорпорейтед Самовосстанавливающийся конденсатор и способы его получения
US9932358B2 (en) 2015-05-21 2018-04-03 Capacitor Science Incorporated Energy storage molecular material, crystal dielectric layer and capacitor
US9941051B2 (en) 2015-06-26 2018-04-10 Capactor Sciences Incorporated Coiled capacitor
US10026553B2 (en) 2015-10-21 2018-07-17 Capacitor Sciences Incorporated Organic compound, crystal dielectric layer and capacitor
US10305295B2 (en) 2016-02-12 2019-05-28 Capacitor Sciences Incorporated Energy storage cell, capacitive energy storage module, and capacitive energy storage system
US10153087B2 (en) 2016-04-04 2018-12-11 Capacitor Sciences Incorporated Electro-polarizable compound and capacitor
US9978517B2 (en) 2016-04-04 2018-05-22 Capacitor Sciences Incorporated Electro-polarizable compound and capacitor
WO2018064529A1 (en) 2016-09-29 2018-04-05 The Uab Research Foundation Methods and compositions for increasing mucus clearance
US10395841B2 (en) 2016-12-02 2019-08-27 Capacitor Sciences Incorporated Multilayered electrode and film energy storage device
WO2021028005A1 (en) * 2019-08-15 2021-02-18 Elkazaz Mohamed Fadly Abd El Ghany A medicament comprising anabasine for treatment of asthma, chest allergy and atopic dermatits

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3247213A (en) * 1961-04-12 1966-04-19 Shell Oil Co Heterocyclic nitrogen compounds
SU530684A1 (ru) * 1971-10-27 1976-10-05 Ташкентский Ордена Трудового Красного Знамени Государственный Университет Им.В.И.Ленина Средство дл лечени хронического никотинизма
US4155909A (en) * 1977-06-13 1979-05-22 Philip Morris Incorporated 2-Alkyl nicotinoids and processes for their production
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
US4360531A (en) * 1981-04-09 1982-11-23 The Upjohn Company Substituted cycloalkanes
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5109017A (en) * 1990-09-26 1992-04-28 Fisons Corporation (2-thienyl)alkylamine derivatives having neuroprotective properties
EP0573568B1 (de) * 1991-03-01 2001-01-24 University Of Florida Research Foundation, Inc. Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems
US5276043A (en) 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function

Also Published As

Publication number Publication date
WO1992015306A1 (en) 1992-09-17
US5602257A (en) 1997-02-11
DE69231658T2 (de) 2001-09-06
JPH06509322A (ja) 1994-10-20
AU652434B2 (en) 1994-08-25
GR3035542T3 (en) 2001-06-29
EP0573568A4 (en) 1994-09-21
DK0573568T3 (da) 2001-04-23
KR0137003B1 (ko) 1998-04-25
US6630491B1 (en) 2003-10-07
EP0573568A1 (de) 1993-12-15
US5516785A (en) 1996-05-14
EP0573568B1 (de) 2001-01-24
CA2105071A1 (en) 1992-09-02
US5840906A (en) 1998-11-24
KR0175638B1 (ko) 1999-02-18
JP2657583B2 (ja) 1997-09-24
ES2153357T3 (es) 2001-03-01
AU1455692A (en) 1992-10-06
CA2105071C (en) 2002-05-14
CA2362719A1 (en) 1992-09-17
DE69231658D1 (de) 2001-03-01

Similar Documents

Publication Publication Date Title
ATE198830T1 (de) Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems
ATE230989T1 (de) Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
ATE196847T1 (de) Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen
FI942965A0 (fi) Taimien kasvatusmenetelmä ja -laite
DE69230040D1 (de) Biokompatibles implantat für die zeitliche abstimmung der ovulation von stuten
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE241981T1 (de) Verwendung von 4-aminopyridin zur behandlung von schmerz und spastik folgende einer verletzung des rückenmarks
ATE78162T1 (de) 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.
ATE190839T1 (de) Verwendung von prodelphidinen zur behandlung von arthrose
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69535263D1 (de) Angiotensin ii zur verbesserung der befruchtung
MX9202015A (es) Esteres aril alquilicos de acido 4,5-di hidroxi -9,10- di hidro-9,10-di oxo --2- antracen carboxilico que tienen actividad terapeutica.
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
ATE203162T1 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one
DE69627298D1 (de) Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten
DE69124382D1 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE200865T1 (de) Verwendung von phosphorderivaten von alkaloiden zur behandlung von endokrinopathien
SI0817786T1 (en) Substituted tetronic acids useful for treating hiv and other retroviruses
DE69620394D1 (de) Verwendung von forskolin oder diese enthaltende extrakte zur herstellung eines medikaments für die behandlung von alkoholsucht

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification